Company: VRCA
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0000950170-25-037172
Chunk: 161

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-03-11
Form: 10-K
Item: Item 1B
Chunk 161
---
 200,000,000 authorized; 91,885,137 shares issued and 91,779,993 shares outstanding as of December 31, 2024 and 42,518,697 shares issued and 42,413,553 shares outstanding as of December 31, 2023

    9

    4

    Treasury stock, at cost, 105,144 shares as of December 31, 2024 and December 31, 2023

    —

    —

    Additional paid-in capital

    297,158

    250,207

    Accumulated deficit

    (307,027
    )

    (230,448
    )

    Total stockholders’ (deficit) equity

    (9,860
    )

    19,763

    Total liabilities and stockholders’ (deficit) equity
     
    $
    54,134

    $
    81,597

The accompanying notes are an integral part of these financial statements.

94

VERRICA PHARMACEUTICALS INC.

STATEMENTS OF OPERATIONS 

(in thousands, except share and per share amounts)

    For the Year Ended December 31,

    2024

    2023

    Revenue:

    Product revenue, net
     
    $
    6,574

    $
    4,658

    Collaboration revenue

    992

    466

    Total revenue

    7,566

    5,124

    Operating expenses:

    Cost of product revenue

    1,853

    289

    Cost of collaboration revenue

    887

    457

    Selling, general and administrative

    58,822

    47,305

    Research and development

    11,840

    20,295

    Loss on disposal of assets

    83

    2,537

    Total operating expenses

    73,485

    70,883

    Loss from operations

    (65,919
    )

    (65,759
    )

    Other (expense) income:

    Interest income

    1,417

    2,740

    Interest expense

    (9,412
    )

    (3,962
    )

    Change in fair value of derivative liability

    (2,648
    )

    —

    Other expense

    (